ONYX THERAPEUTICS, INC.
Patent Owner
Stats
- 46 US PATENTS IN FORCE
- 3 US APPLICATIONS PENDING
- Jan 30, 2018 most recent publication
Details
- 46 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 1,722 Total Citation Count
- Apr 14, 2005 Earliest Filing
- 16 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2016/0177,402 IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSEAug 08, 14Jun 23, 16[A61K, C12Q, G01N]
2015/0209,282 LIPOSOMAL COMPOSITIONS OF EPOXYKETONE-BASED PROTEASOME INHIBITORSJul 17, 13Jul 30, 15[A61K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9403868 Crystalline tripeptide epoxy ketone protease inhibitorsMar 05, 15Aug 02, 16[A61K, C07D, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0209,281 LIPOSOMAL COMPOSITIONS OF EPOXYKETONE-BASED PROTEASOME INHIBITORSAbandonedJul 17, 13Jul 30, 15[A61K]
2014/0105,921 Prodrugs of Peptide Epoxy Ketone Protease InhibitorsAbandonedJul 09, 13Apr 17, 14[A61K, C07K]
2013/0303,465 Cylodextrin Complexation Methods for Formulating Peptide Proteasome InhibitorsAbandonedSep 13, 12Nov 14, 13[A61K, A61P]
2013/0303,482 Cylodextrin Complexation Methods for Formulating Peptide Proteasome InhibitorsAbandonedSep 13, 12Nov 14, 13[A61K, A61P]
2012/0329,705 COMPOUNDS FOR PROTEASOME ENZYME INHIBITIONAbandonedJun 08, 12Dec 27, 12[A61K, A61P, C07K]
2011/0236,428 COMBINATION THERAPY WITH PEPTIDE EPOXYKETONESAbandonedOct 21, 09Sep 29, 11[A61K, A61P]
2010/0240,903 CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORSAbandonedMar 22, 10Sep 23, 10[C07D]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.